Novo Nordisk gives back with summer camp grants
PRINCETON, N.J. Novo Nordisk has given out $165,000 in grants to support summer camps for children with diabetes, the Danish drug maker announced Monday.
The company said the grants would support scholarships and fund capital improvements at 15 camps around the country.
“Novo Nordisk recognizes the important positive impact that diabetes camps can make in helping children and families with diabetes lead healthier, happier and more productive lives,” Novo Nordisk president Jerzy Gruhn said. ”By helping children and families with diabetes discover ways to manage diabetes and start developing skills to help take care of oneself, the camps are helping to change diabetes – how it is treated, how it is viewed and how the disease evolves in the future.”
Late-stage clinical trial of Avastin fails to meet expectations, Genentech says
SOUTH SAN FRANCISCO, Calif. A late-stage clinical trial of a Genentech drug for men with late-stage prostate cancer has failed, the biotech company announced Friday.
Genentech, part of Swiss drug maker Roche, announced that a phase 3 trial of Avastin (bevacizumab) combined with prednisone and the chemotherapy drug docetaxel did not extend the amount of time that patients survived, compared with chemotherapy and prednisone alone.
The drug already has approval from the Food and Drug Administration for treating tumors and cancers of the lungs, colon, rectum, breasts, kidneys and brain.
Abbott’s submits supplemental approval application for Lupron Depot to FDA
ABBOTT PARK, Ill. Abbott is hoping that the Food and Drug Administration will approve one of its drugs as a treatment for advanced prostate cancer.
The Chicago-based drug maker announced Thursday that the FDA accepted its supplemental approval application for Lupron Depot (leuprolide acetate) in the 45-mg strength. The drug, an injectable, works by suppressing production of testosterone for six months. It is currently available in 7.5-mg, 22.5-mg and 30-mg formulations that work for one, three and four months.
“For many patients with advanced prostate cancer, Lupron Depot is an important treatment option because it can help manage the symptoms of their disease,” Abbott VP global pharmaceutical development Eugene Sun said in a statement. “Abbott is seeking approval for a new six-month formulation to provide greater convenience and dosing flexibility to physicians and patients who could benefit form this medication.”